Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIDH.L Regulatory News (IDH)

  • There is currently no data for IDH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

5 Oct 2009 07:00

RNS Number : 1958A
Immunodiagnostic Systems Hldgs PLC
05 October 2009
 



 

Immunodiagnostic Systems Holdings plc

Trading update

Immunodiagnostic Systems Holdings plc ("IDS" or "the Company"), a leading producer of diagnostic testing kits for the clinical and research markets, announces a trading update for the six month period to 30 September 2009, prior to the release of its half-yearly report on Monday, 30 November 2009.

Turnover from continuing operations for the period is 56% ahead of the comparative period for last year at £16.9 million (2008: £10.8 million) and 20% ahead of 2008 H2 on a like for like basis. Revenues have increased in all direct sales territories with substantial growth in the USAFrance and Germany. Sales of our Vitamin D products continue to grow at an impressive rate, having doubled compared to same period last year.

The company has made progress in both sales and placements of our automated instrument the IDS-iSYS following its launch at the end of February this yearWe have also launched three automated products; 25 Hydroxy vitamin D at the end of February, P1NP in July and HGH in September. We have direct reagent rental accounts in the UK, FranceGermanyAustria 

and Switzerland and have made instrument sales in AustraliaCanadaFinlandItalySpainFrance and Switzerland.

The roll out of the IDS-iSYS is in its formative stages, and although initial machine sales are a little lower than anticipated, it is pleasing to report that revenue per machine is ahead of expectations. We expect the rate of sales and placements to increase in H2 following the increase in the number of iSYS evaluation sites towards the end of H1, the new agreement with Technogenetics (announced today on RNS Reach) under which we will supply OEM instruments and reagents to them, and, subject to the timing of FDA approval later this year, the planned US launch of the iSYS system.

Overall trading remains in line with management expectations and the Board remains confident going forward that it can continue to execute its plans for the current year.

Enquiries:

Immunodiagnostic Systems Holdings Plc

Tel: 0191 519 0660

Roger Duggan, CEO

Paul Hailes, Finance Director

Brewin Dolphin Investment Banking

Tel: 0845 213 4730

Andrew Emmott

Sean Wyndham-Quin

Walbrook PR Ltd

Tel: 020 7933 8787

Paul McManus

Mob: 07980 541 893

paul.mcmanus@walbrookpr.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTILFLTIRLSIIA
Date   Source Headline
1st Jun 20117:00 amRNSAppointment of Non-Executive Director
9th May 20117:00 amRNSChange of contract terms
28th Apr 20117:00 amRNSTotal Voting Rights
12th Apr 20118:34 amRNSExercise of Share Options and Total Voting Rights
6th Apr 20117:00 amRNSTrading update
28th Mar 20117:35 amRNSExclusive Licence Agreement
1st Mar 20117:00 amRNSDirector/PDMR Shareholding
3rd Feb 201110:34 amRNSDirector/PDMR Shareholding
11th Jan 20113:40 pmRNSDirector/PDMR Shareholding
30th Nov 20107:00 amRNSHalf Yearly Report
12th Nov 20104:41 pmRNSSecond Price Monitoring Extn
12th Nov 20104:35 pmRNSPrice Monitoring Extension
1st Nov 201011:22 amRNSHolding(s) in Company
5th Oct 20108:56 amRNSPosting of Report and Accounts and Notice of AGM
5th Oct 20107:00 amRNSTrading Update
27th Sep 20107:00 amRNSIssue of Equity
21st Sep 20104:35 pmRNSPrice Monitoring Extension
20th Sep 201010:33 amRNSHolding(s) in Company
13th Sep 20107:00 amRNSAcquisition & Research Agreement
25th Aug 20104:06 pmRNSResult of AGM
25th Aug 20107:00 amRNSAGM Statement
26th Jul 20101:00 pmRNSExercise of Share Options and Total Voting Rights
26th Jul 20107:00 amRNSNew specialist assay launched for IDS-iSYS
20th Jul 20107:00 amRNSDirector/PDMR Shareholding
12th Jul 20107:00 amRNSDirectorate Change
12th Jul 20107:00 amRNSFinal Results
29th Jun 20107:00 amRNSReceipt of FDA 510(k) clearances
16th Jun 20104:40 pmRNSSecond Price Monitoring Extn
16th Jun 20104:35 pmRNSPrice Monitoring Extension
14th Jun 20104:35 pmRNSPrice Monitoring Extension
11th Jun 20104:35 pmRNSPrice Monitoring Extension
10th Jun 20104:35 pmRNSPrice Monitoring Extension
26th May 20104:40 pmRNSSecond Price Monitoring Extn
26th May 20104:35 pmRNSPrice Monitoring Extension
10th May 20107:00 amRNSExercise of Share Options
12th Apr 20107:00 amRNSTrading Statement
31st Mar 201012:24 pmRNSTotal Voting Rights
31st Mar 20107:00 amRNSNew specialist assays launched for IDS-iSYS
22nd Mar 20107:00 amRNSDirector/PDMR Shareholding
16th Mar 201010:00 amRNSDirector/PDMR Shareholding
23rd Feb 201011:47 amRNSExercise of Share Options
9th Feb 20107:00 amRNSShare options
1st Feb 20109:13 amRNSExercise of Share Options and Total Voting Rights
4th Jan 20107:00 amRNSFive year distribution agreement
21st Dec 20091:15 pmRNSDirector/PDMR Shareholding
18th Dec 20093:18 pmRNSIssue of Equity
11th Dec 20097:00 amRNSDirectorate Change
10th Dec 20097:00 amRNSExercise of Share Options and Directors' Dealings
30th Nov 20097:00 amRNSHalf Yearly Report
18th Nov 200910:03 amRNSDirectorate Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.